ArticleCancer immunology, immunotherapy : CII2007
Immune reconstitution prevents metastatic recurrence of murine osteosarcoma.
Article in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- <p>Tumor microenvironment in bone sarcomas: Implications for immunotherapy and emerging therapeutic vulnerabilities (Review)</p>.Oncology reports · 2026Review
- Signature of immune infiltration-related ferroptosis genes to predict the prognosis of patients with osteosarcoma.Oncology letters · 2025Article
- Risk score model with two immune infiltration-related long non-coding RNAs to predict prognosis in patients with osteosarcoma.Oncology letters · 2025Article
- Article
- Targeting metastasis in paediatric bone sarcomas.Molecular cancer · 2025Review
- The expression changes of PD-L1 and immune response mediators are related to the severity of primary bone tumors.Scientific reports · 2023Article
- Identification of prognostic biomarkers associated with metastasis and immune infiltration in osteosarcoma.Oncology letters · 2021Article
- Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma.Diagnostics (Basel, Switzerland) · 2020Article
- Detection of circulating tumor DNA in patients with osteosarcoma.Oncotarget · 2018Article
- Bioinformatics analysis of differentially expressed pathways related to the metastatic characteristics of osteosarcoma.International journal of molecular medicine · 2016Article
- Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach.Veterinary sciences · 2016Review
- Potential role of S-adenosylmethionine in osteosarcoma development.OncoTargets and therapy · 2016Article
- Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients.Journal for immunotherapy of cancer · 2015Article
- Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.Oncotarget · 2014Article
- Potential of human γδ T cells for immunotherapy of osteosarcoma.Molecular biology reports · 2013Review
- Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.Pediatric blood & cancer · 2011Article
- Immune-based therapeutics for pediatric cancer.Expert opinion on biological therapy · 2010Review
- Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.The Journal of biological chemistry · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Primary tumors developing in immunocompetent hosts escape immunosurveillance by acquiring immune evasive properties. This raises the prospect that metastases derived from such tumors will also evade immunity. To investigate whether immune surveillance plays a role in preventing metastases, we studied a murine model which mimics the clinical progression of osteosarcoma: primary tumor growth in the lower extremity, amputation, minimal residual disease followed by the development of overt metastases. K7M2 implants readily escaped immune surveillance since normal BALB/c mice, T cell deficient SCID and T/NK cell deficient SCID-bg mice showed no difference in the rate of growth of primary osteosarcomas. However, both SCID and SCID-bg mice had higher rates of metastases than immunocompetent mice. Similarly, immune reconstitution following transfer of naive T cells to SCID or SCID-bg mice did not impact primary tumor growth, but significantly diminished metastatic recurrence. T cells in osteosarcoma bearing mice produced IFNgamma in response to tumor and IFNgamma production by immune reconstituting T cells was required to prevent metastases. These results demonstrate an important role for T cell based immune surveillance in preventing metastases, even when metastases develop from tumors that adeptly evade immunosurveillance. The results further suggest that T cell depleting cancer therapies may eliminate beneficial immune responses and that immune reconstitution of lymphopenic cancer patients could prevent metastatic recurrence of solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.